Send to

Choose Destination
Alzheimers Dement (Amst). 2019 Mar 15;11:270-276. doi: 10.1016/j.dadm.2019.01.006. eCollection 2019 Dec.

A proteomic signature for dementia with Lewy bodies.

Author information

Institute for Translational Research, Department of Pharmacology & Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, USA.
Department of Psychiatry and Psychology, Mayo Clinic, Jacksonville, FL, USA.
Vermont Genetics Network, University of Vermont, Burlington, VT, USA.
Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Department of Neuro-Oncology, MD Anderson Cancer Center, Houston, TX, USA.



We sought to determine if a proteomic profile approach developed to detect Alzheimer's disease would distinguish patients with Lewy body disease from normal controls, and if it would distinguish dementia with Lewy bodies (DLB) from Parkinson's disease (PD).


Stored plasma samples were obtained from 145 patients (DLB n = 57, PD without dementia n = 32, normal controls n = 56) enrolled from patients seen in the Behavioral Neurology or Movement Disorders clinics at the Mayo Clinic, Florida. Proteomic assays were conducted and analyzed as per our previously published protocols.


In the first step, the proteomic profile distinguished the DLB-PD group from controls with a diagnostic accuracy of 0.97, sensitivity of 0.91, and specificity of 0.86. In the second step, the proteomic profile distinguished the DLB from PD groups with a diagnostic accuracy of 0.92, sensitivity of 0.94, and specificity of 0.88.


These data provide evidence of the potential utility of a multitiered blood-based proteomic screening method for detecting DLB and distinguishing DLB from PD.


Biomarker screening; Blood biomarkers; Dementia with Lewy bodies; Detection; Diagnostic accuracy; Parkinson's disease; Proteomics

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center